Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation-A nationwide descriptive study in Taiwan

Clinical Therapeutics

Volumn 30, Issue 9, 2008, Pages 1726-1736

  Lin, Li Jen ^a   Cheng, Ming Hui ^a   Lee, Cheng Han ^a   Wung, Der Chang ^a   Cheng, Ching Lan ^a   Kao Yang, Yea Huei ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

anticoagulation; antithrombotic therapy; atrial fibrillation; stroke; warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; TICLOPIDINE; WARFARIN;

ADULT; AGED; ARTICLE; BLEEDING; CORONARY ARTERY DISEASE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; RISK FACTOR; STROKE; THYROTOXICOSIS;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; DRUG PRESCRIPTIONS; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS; STROKE; TAIWAN; WARFARIN;

EID: 54749114827     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.09.010     Document Type: Article

References (23)

1. Hart R.G., Benavente O., McBride R., and Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 131 (1999) 492-501
2. Singer D.E., Albers G.W., Dalen J.E., et al. Antithrombotic therapy in atrial fibrillation: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 Suppl 3 (2004) 429S-456S
3. Fuster V., Rydén L.E., Cannom D.S., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines; the European Society of Cardiology Committee for Practice Guidelines; the European Heart Rhythm Association; and the Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society [published correction appears in Circulation. 2007;116:e138]. Circulation 114 (2006) e257-e354
4. Fuster V., Rydén L.E., Asinger R.W., et al., American College of Cardiology/American Heart Association/European Society of Cardiology Board. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): Developed in collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 38 (2001) 1231-1266
5. Go A.S., Hylek E.M., Borowsky L.H., et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 131 (1999) 927-934
6. Waldo A.L., Becker R.C., Tapson V.F., et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. J Am Coll Cardiol 46 (2005) 1729-1736
7. Friberg L., Hammar N., Ringh M., et al. Stroke prophylaxis in atrial fibrillation: Who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 27 (2006) 1954-1964
8. White R.H., McBurnie M.A., Manolio T., et al. Oral anticoagulation in patients with atrial fibrillation: Adherence with guidelines in an elderly cohort. Am J Med 106 (1999) 165-171
9. Glazer N.L., Dublin S., Smith N.L., et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med 167 (2007) 246-252
10. Reynolds M.R., Shah J., Essebag V., et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol 97 (2006) 538-543
11. Johnston J.A., Cluxton Jr. R.J., Heaton P.C., et al. Predictors of warfarin use among Ohio Medicaid patients with new-onset nonvalvular atrial fibrillation. Arch Intern Med 163 (2003) 1705-1710
12. Cohen N., Almoznino-Sarafian D., Alon I., et al. Warfarin for stroke prevention still underused in atrial fibrillation: Patterns of omission. Stroke 31 (2000) 1217-1222
13. Bungard T.J., Ghali W.A., Teo K.K., et al. Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med 160 (2000) 41-46
14. Nieuwlaat R., Capucci A., Camm A.J., et al., European Heart Survey Investigators. Atrial fibrillation management: A prospective survey in ESC member countries: The Euro Heart Survey on Atrial Fibrillation. Eur Heart J 26 (2005) 2422-2434
15. Indredavik B., Rohweder G., and Lydersen S. Frequency and effect of optimal anticoagulation before onset of ischaemic stroke in patients with known atrial fibrillation. J Intern Med 258 (2005) 133-144
16. Khor G.L. Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr 10 (2001) 76-80
17. NHI profile (updated 2008.07.07) [Bureau of National Health Insurance Web site]. http://www.nhi.gov.tw/english/webdata.asp?menu=11&menu_id=290&we bdata_id=1884 Accessed September 1, 2008.
18. Cheung C.M., Tsoi T.H., and Huang C.Y. The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation. Cerebrovasc Dis 20 (2005) 114-119
19. Yasaka M., Minematsu K., and Yamaguchi T. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation. Intern Med 40 (2001) 1183-1188
20. You J.H., Chan F.W., Wong R.S., and Cheng G. Is INR between 2.0 and 3.0 the optimal level for Chinese patients on warfarin therapy for moderate-intensity anticoagulation?. Br J Clin Pharmacol 59 (2005) 582-587
21. Odén A., Fahlén M., and Hart R.G. Optimal INR for prevention of stroke and death in atrial fibrillation: A critical appraisal. Thromb Res 117 (2006) 493-499
22. Cabana M.D., Rand C.S., Powe N.R., et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282 (1999) 1458-1465
23. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 285 (2001) 2864-2870